Tumor histopathology following new sensitizers: dithiaporphyrin- and sulfoxaporphyrin-mediated photodynamic therapy.

Abstract

BACKGROUND:

Our main aim was to evaluate tumor histopathology following new sensitizer-mediated photodynamic therapy (PDT).

MATERIALS AND METHODS:

In order to complete our studies we decided to use photosensitizers, i.e. dithiaporphyrin (DTP) and sulfoxaporphyrin (OXA) in combination with halogen lamp irradiation of presensitized tumors. The doses of sensitizers were: 2.5, 5.0, 7.5 and 10.0 mg/kg of body weight and total light doses were: 50, 100 and 150 J/sq.cm at the selected wavelength. Following such a treatment we have evaluated tumor necrosis of BFS1 fibrosarcoma growing on BALB/c mice. Together with tumor necrosis evaluation we have examined skin response to photodynamic treatment.

RESULTS:

We have found that both new sensitizers caused significant tumor damage at no skin alterations. The induction of tumor necrosis seemed to be dose dependent, i.e. higher photodynamic doses (sensitizer dose x light dose) resulted in more severe damage to the tumors than the lower doses.

CONCLUSION:

Our study showed that BFS1 fibrosarcoma is highly sensitive to PDT after application of new sensitizers. Both compounds can be considered as potent tumor photosensitizers in future clinical trials.

• Authors: K Symonowicz, P Ziólkowski, P Chmielewski, L Latos-Grazynski, J Rabczynski, B J Osiecka, J Milach
• Journal: Anticancer research (Anticancer Res) 1999 Nov-Dec Vol. 19 Issue 6B Pg. 5385-91 ISSN: 0250-7005 [Print] Greece
• PMID: 10697566 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 21,23-dithiaporphyrin
• 21-oxaporphyrin
• Photosensitizing Agents
• Porphyrins

Topics

• Animals
• Fibrosarcoma (drug therapy, pathology)
• Mice
• Mice, Inbred BALB C
• Photochemotherapy
• Photosensitizing Agents (pharmacology, therapeutic use)
• Porphyrins (pharmacology, therapeutic use)